Acuta Capital Partners’s Ascendis Pharma A/S ASND Stock Holding History

Acuta Capital Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,792	Closed	-$1.95M	–	31
2025 Q3	$1.95M	Sell	9,792 -12,784	-57%	-$2.38M	2.01%	14
2025 Q2	$3.9M	Sell	22,576 -764	-3%	-$124K	5.44%	6
2025 Q1	$3.64M	Buy	23,340 +364	+2%	+$52K	4.22%	9
2024 Q4	$3.16M	Buy	22,976 +1,976	+9%	+$260K	3.18%	12
2024 Q3	$3.14M	Buy	+21,000	New	+$2.84M	2.54%	17
2020 Q3	–	Sell	-55,500	Closed	-$8.21M	–	49
2020 Q2	$8.21M	Sell	55,500 -7,700	-12%	-$1.06M	2.37%	16
2020 Q1	$7.12M	Buy	63,200 +40,700	+181%	+$5.29M	3.45%	11
2019 Q4	$3.13M	Buy	+22,500	New	+$2.5M	0.78%	30
2018 Q4	–	Sell	-71,500	Closed	-$5.07M	–	25
2018 Q3	$5.07M	Sell	71,500 -239,611	-77%	-$16.5M	1.81%	17
2018 Q2	$20.7M	Sell	311,111 -232,889	-43%	-$15.3M	3.68%	8
2018 Q1	$35.6M	Buy	544,000 +13,000	+2%	+$731K	5.81%	5
2017 Q4	$21.3M	Buy	531,000 +31,000	+6%	+$1.13M	4.02%	7
2017 Q3	$18.1M	Sell	500,000 -424,483	-46%	-$12.2M	3.25%	9
2017 Q2	$25.7M	Buy	924,483 +374,483	+68%	+$9.89M	7.18%	3
2017 Q1	$15.4M	Sell	550,000 -25,309	-4%	-$640K	3.65%	8
2016 Q4	$11.6M	Buy	575,309 +212,309	+58%	+$4.24M	4.33%	8
2016 Q3	$7.3M	Sell	363,000 -109,800	-23%	-$1.81M	2.74%	10
2016 Q2	$6.27M	Sell	472,800 -150,831	-24%	-$2.32M	3.01%	10
2016 Q1	$11.6M	Buy	623,631 +104,388	+20%	+$1.85M	6.47%	6
2015 Q4	$9.51M	Buy	519,243 +49,350	+11%	+$865K	4.55%	6
2015 Q3	$8.32M	Buy	469,893 +48,042	+11%	+$935K	4.81%	4
2015 Q2	$7.46M	Buy	421,851 +193,239	+85%	+$3.38M	4.61%	6
2015 Q1	$3.97M	Buy	+228,612	New	+$4.16M	3.34%	7

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acuta Capital Partners's ASND Position: Q4 2025 in Review

Acuta Capital Partners sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 9,792 shares — an estimated $1.95M sold.

Acuta Capital Partners first reported a position in ASND in Q1 2015 and held it in 23 quarters. The position peaked at $35.6M in Q1 2018. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Acuta Capital Partners reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Acuta Capital Partners sold 9,792 Ascendis Pharma A/S shares in Q4 2025, an estimated $1.95M.
Acuta Capital Partners first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 23 quarters.
Acuta Capital Partners's Ascendis Pharma A/S position peaked at $35.6M in Q1 2018.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Acuta Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.